A
AEYE Health
AEYE Health is a digital health company that aims to enable automated, AI-based retinal screening
About AEYE Health
AEYE Health, a digital health firm established in 2018, operates from New York and Tel Aviv. The company was co-founded by Zack Dvey-Aharon, PhD, and Danny Margalit. Dvey-Aharon, the CEO, is a serial entrepreneur with a PhD in machine learning from Tel Aviv University and a background in the Israeli Defense Forces' intelligence corps. His interest in the field began at a young age and was solidified during his PhD research, where he recognized the eye's potential as a mirror to the body's health. Margalit, the COO, previously co-founded Aladdin, which had a NASDAQ IPO.
The company's core business revolves around providing fully autonomous, AI-powered diagnostic screening solutions for retinal imaging. This technology is designed to be integrated into primary care settings, endocrinology clinics, pharmacies, and even home-care environments, making retinal screenings more accessible and affordable. By enabling non-specialists to conduct these screenings, AEYE Health aims to increase adherence to annual eye exams, particularly for the millions of diabetic patients at risk of diabetic retinopathy, a leading cause of blindness in working-age adults. The business model is supported by a CPT code for autonomous AI-based screening, which allows healthcare providers to be reimbursed for the service.
AEYE Health's flagship product is the AEYE-DS, an AI-based system that analyzes retinal images to detect various conditions. In November 2022, the company received its first FDA 510(k) clearance to market the system for detecting more-than-mild diabetic retinopathy. A significant milestone occurred in April 2024, when AEYE Health secured a second FDA clearance for its technology to be used with a portable, handheld camera, the Optomed Aurora. This clearance established the AEYE-DS as the first fully autonomous AI solution cleared for use with both portable and tabletop devices. The system delivers diagnostic results in under a minute, using just a single image per eye, and rarely requires pupil dilation, enhancing its usability in point-of-care settings. Clinical studies demonstrated high sensitivity and specificity for the technology. Beyond diabetic retinopathy, the company is developing its platform to screen for other conditions like glaucoma, AMD, hypertension, and cardiovascular risk.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 81.8/100
- Industry
- Health
- Sub-industry
- Medical Devices, Health Platform
- Sector
- Data Analytics, Predictive Analytics, Screening, Non-Invasive medical devices and treatments, Clinical Decision Support, Tech for Medical Professionals
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Machine Learning
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2022 | $10M | $40M | Undisclosed | — |
| SEEDEquity / VC | Jan 2022 | $10M | $40M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for AEYE Health is 4.7K monthly website visits, down 20.3% over the last three months. AEYE Health's team grew 5.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AEYE Health in the Tel Aviv-Yafo ecosystem
The AEYE Health office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Sky Ventures Group- FVFalcon Ventures
- CPClub 100 Plus
BioLight Israeli Life Sciences Investments Ltd
Sean Ianchulev- 1C100 Club
SK
Other known investors2 additional known investors
Mike Netz
OurCrowd
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AEYE Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AEYE Health’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










